Publicaciones en colaboración con investigadores/as de Hospital de la Santa Creu i Sant Pau (18)

2024

  1. RET Fusion Testing in Patients With NSCLC: The RETING Study

    JTO Clinical and Research Reports, Vol. 5, Núm. 4

2023

  1. Amivantamab plus Chemotherapy in NSCLC with EGFR Exon 20 Insertions

    New England Journal of Medicine, Vol. 389, Núm. 22, pp. 2039-2051

  2. Tarlatamab for Patients with Previously Treated Small-Cell Lung Cancer

    New England Journal of Medicine, Vol. 389, Núm. 22, pp. 2063-2075

  3. p53 and ovarian carcinoma survival: an Ovarian Tumor Tissue Analysis consortium study

    Journal of Pathology: Clinical Research, Vol. 9, Núm. 3, pp. 208-222

2021

  1. Impact of the COVID-19 pandemic on the care of cancer patients in Spain

    ESMO open, Vol. 6, Núm. 3, pp. 100157

  2. LungBEAM: A prospective multicenter study to monitor stage IV NSCLC patients with EGFR mutations using BEAMing technology

    Cancer Medicine, Vol. 10, Núm. 17, pp. 5878-5888

  3. Pd-(L)1 inhibitors as monotherapy for the first-line treatment of non-small-cell lung cancer patients with high pd-l1 expression: A network meta-analysis

    Journal of Clinical Medicine, Vol. 10, Núm. 7

  4. Predicting immunotherapy outcomes under therapy in patients with advanced NSCLC using dNLR and its early dynamics

    European Journal of Cancer, Vol. 151, pp. 211-220

2017

  1. Long-term survival in advanced non-squamous NSCLC patients treated with first-line bevacizumab-based therapy

    Clinical and Translational Oncology, Vol. 19, Núm. 2, pp. 219-226

  2. Strategies to design clinical studies to identify predictive biomarkers in cancer research

    Cancer Treatment Reviews, Vol. 53, pp. 79-97

2012

  1. Complete longitudinal analyses of the randomized, placebo-controlled, phase III trial of sunitinib in patients with gastrointestinal stromal tumor following imatinib failure

    Clinical Cancer Research, Vol. 18, Núm. 11, pp. 3170-3179

  2. Recommendations for the optimal management of early and advanced urothelial carcinoma

    Cancer Treatment Reviews, Vol. 38, Núm. 5, pp. 431-441

  3. Trabectedin in pre-treated patients with advanced or metastatic soft tissue sarcoma: A phase II study evaluating co-treatment with dexamethasone

    Investigational New Drugs, Vol. 30, Núm. 2, pp. 729-740

2010

  1. Update from the Spanish Oncology Genitourinary Group on the treatment of advanced renal cell carcinoma: Focus on special populations

    Cancer and Metastasis Reviews, Vol. 29, Núm. SUPPL. 1

  2. Updated recommendations from the Spanish Oncology Genitourinary Group on the treatment of advanced renal cell carcinoma

    Cancer and Metastasis Reviews, Vol. 29, Núm. SUPPL. 1

2004

  1. Incidence of contralateral germ cell testicular tumors in south Europe: Report of the experience at 2 Spanish university hospitals and review of the literature

    Journal of Urology, Vol. 171, Núm. 1, pp. 164-167

2003

  1. Multicenter study evaluating a dual policy of postorchiectomy surveillance and selective adjuvant single-agent carboplatin for patients with clinical stage I seminoma

    Annals of Oncology, Vol. 14, Núm. 6, pp. 867-872

2002

  1. Phase II multicentre study of docetaxel plus cisplatin in patients with advanced urothelial cancer

    British Journal of Cancer, Vol. 86, Núm. 3, pp. 326-330